Our extensive database of Harvard technologies is available for new product development opportunities that will strengthen your strategic portfolio.

The Harvard University Office of Technology Development (OTD) provides a one-stop shop to advance the development of groundbreaking discoveries by fostering strategic collaborations with industry through licensing, sponsored research and new venture agreements.

Impact

Turning today's discoveries into tomorrow's transformational technologies.

By serving as a catalyst bridging the laboratory to industry, OTD ensures that promising new technologies are developed into products and services that benefit society and transform the world.

Leadership

Leading the way in discovery and application.

Harvard is a recognized world leader in discovery and innovation. Leadership means the determination to see that new technologies developed at Harvard reach their full potential and push the boundaries of the new scientific and industrial frontier.

Experience

At OTD, experience is a competitive advantage.

OTD's high performance team provides a solid foundation in science, business development, intellectual property and contract law that enables it to design creative "win-win" solutions that translate into enduring, fruitful relationships. When industry turns to OTD, it will find an agile, fast-paced group of professionals fully equipped to find creative solutions and make the deal-making process as efficient and effective as possible.

Partnership

The power of collaborative partnering.

Partnership is a vital pillar, a linchpin of OTD's business model. We have the focus, commitment and expertise to forge creative and productive partnerships. OTD is dedicated to fostering win/win relationships between faculty and industry, investors and entrepreneurs, relationships that will provide mutual and long-lasting benefit.

Blavatnik Biomedical Accelerator

Propelling promising Harvard life science innovations to partnership

To positively impact society, biomedical technology breakthroughs must first make the leap from the research lab to the commercial sphere. The Blavatnik Biomedical Accelerator at Harvard University is uniquely structured to bridge that gap, helping propel groundbreaking innovations toward next-generation products.

Available Technology

Treatment of AMD by Targeting Lipocuscin



Markets Addressed


Age-related macular degeneration affects about 14 million people in the US and is expanding with the aging of the population. In this disease, daytime vision (cone dominated vision) degrades with time because cone photoreceptors, which are concentrated in the foveal region of the retina, die. Despite the fact that current treatment of AMD are targeting the wet form of AMD, accounting for only about 10% of AMD cases, the market for therapeutics is growing rapidly toward annual sales of $1 billion. Therefore, enabling treatment of the dry form of AMD by Dr. Rando’s approach presents an opportunity not only to relieve an extremely large patient population of a debilitating clinical condition, but also create a commercially attractive multi-billion dollar market.

Commercial Applications:
Therapeutics for the treatment of AMD and Stargadt disease.

Innovations and Advantages


The invention encompasses a new approach for the treatment of macular degeneration, in particular to dry form of age-related macular degeneration (AMD). It consists of a series of small molecule compounds that eliminate the accumulation of retinotoxic Lipofuscin, a byproduct of the visual process. The accumulation of Lipofuscin is known to cause dry AMD. Rando’s approach enables Lipofuscin elimination by limiting the turnover of the visual cycle. Known inhibitors of the visual cycle are mostly toxic retinoids. Rando has identified multiple targets in the visual cycle as well as a series of non-retinoid compounds which are anticipated not to share this toxicity. Key targets and the efficacy of several prototypical compounds have been validated in vitro and in animals with no apparent toxicity.


Availability & Patent Status

Patents have been broadly filed for compositions of matter as well as methods of use of a series on non-retinoid compounds, including the generic structure of fenretinide, in treating ocular disease. The technology is available for international licensing on an exclusive basis.

Additional Information


Intellectual Property Status: Issued U.S. patent nos.: 7,566,808





Inventor(s):
    Rando, Robert R.

Categories:
For further information, please contact:
Grant Zimmermann, Director of Business Development
(617) 495-3067
Reference Harvard Case #2252